Message :
Required fields AFM24 preclinical in vivo data will be presented as a poster Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, announced today that preclinical
anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) )
AFM24 have been accepted for e-poster presentation at the American
Association for Cancer Research (AACR) Virtual Annual Meeting I, being
held on April 10-15. In addition, early data from a Phase 1 study evaluating AFM13 preloaded
FTSE 100 cuts losses; Wall Street to see mixed open
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
FTSE 100 flattens; AstraZeneca plc dips after EU countries halt COVID-19 vaccine over blood clots concerns
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Immunocore Announces Upcoming Presentations at the American Association for Cancer Research .
Immunocore Holdings PlcMarch 11, 2021 GMT
OXFORDSHIRE, England and CONSHOHOCKEN, Penn. and ROCKVILLE, Md., March 10, 2021 (GLOBE NEWSWIRE) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that four abstracts highlighting the Company’s lead program, tebentafusp, were accepted at the American Association for Cancer Research (AACR) 2021 Annual Meeting, which will be held virtually from April 10-15, 2021. Two abstracts will be presented as oral presentations including, in the plenary session, Phase 3 data comparing tebentafusp (IMCgp100) with investigator’s choice in first li
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer .
CRISPR Therapeutics AGMarch 10, 2021 GMT
ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from April 10 to 15 and May 17 to 21, 2021.
Title: CD70 knockout: A novel approach to augment CAR-T cell function Session Title: Adoptive Cell Therapy